In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
-- Preliminary results from phase 1 study demonstrate a 46.7 percent overall response rate and 100 percent disease control rate with smart chemotherapy DS-8201 in a subgroup analysis of HER2-expressing metastatic breast cancer pre-treated with T-DM1 and pertuzumab
- BLU-285 receives Breakthrough Therapy Designation for the treatment of patients with unresectable or metastatic GIST harboring the PDGFRα D842V mutation -
- Nintedanib plus standard chemotherapy (pemetrexed/cisplatin) demonstrated a 46% reduction in the risk of disease progression in patients with inoperable malignant pleural mesothelioma (MPM) compared to placebo plus standard chemotherapy